Combination Inhalers Containing Inhaled Corticosteroids and Long-Acting β₂-Agonists: Improved Clinical Efficacy and Dosing Options in Patients with Asthma

References

• Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. National Institutes of Health: National Heart, Lung, and Blood Institute. Bethesda, MD: National Institutes of Health, 2002. (Publication no. NIH-NHLI 02-3569).
   Google Scholar
• British Thoracic Society. British guidelines on the management of asthma.Thorax 2003; 58(suppl 1):1–94. [CSA]
   PubMedGoogle Scholar
• Barnes P J, Pedersen S, Busse W W. Efficacy and safety of inhaled corticosteroids. New developments.Am J Respir Crit Care Med 1998; 157(3 Pt 2):S1–S53. [CSA]
   PubMed Web of Science ®Google Scholar
• Ebeling P R, Erbas B, Hopper J L, Wark J D, Rubinfeld A R. Bone mineral density and bone turnover in asthmatics treated with long-term inhaled or oral glucocorticoids.J Bone Miner Res 1998; 13:1283–1289. [CSA]
   PubMed Web of Science ®Google Scholar
• Lipworth B J, Jackson C M. Safety of inhaled and intranasal corticosteroids. Lessons for the new millennium.Drug Saf 2000; 23:11–33. [CSA]
   PubMed Web of Science ®Google Scholar
• Greening A P, Ind P W, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid.Lancet 1994; 344:219–224. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Woolcock A, Lundback B, Ringdal N, Jacques L A. Comparison of addition of salmeterol to inhaled steroids with doubling the dose of inhaled steroids.Am J Respir Crit Care Med 1996; 153:1481–1488., [CSA]
   PubMed Web of Science ®Google Scholar
• Pauwels R A, Lofdahl C.-G, Postma D S, Tattersfield A E, O'Byrne P, Barnes P J, Ullman A. Effect of inhaled formoterol and budesonide on exacerbations of asthma.N Engl J Med 1997; 337:1405–1411. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jenkins C, Woolcock A J, Saarelainen P, Lundbäck B, James M H. Salmeterol/fluticasone propionate combination therapy 50/250 µg twice daily is more effective than budesonide 800 µg twice daily in treating moderate to severe asthma.Respir Med 2000; 94:715–723. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lipworth B J. Airway subsensitivity with long-acting beta 2-agonists. Is there cause for concern?. Drug Saf 1997; 16:295–308. [CSA]
   PubMed Web of Science ®Google Scholar
• McIvor R A, Pizzichini E, Turner M O, Hussack P, Hargreave F E, Sears M R. Potential masking of effects of salmeterol on airway inflammation in asthma.Am J Respir Crit Care Med 1998; 158:924–930. [CSA]
   PubMed Web of Science ®Google Scholar
• Kips J C, O'Connor B J, Inman M D, Svensson K, Pauwels R A, O'Byrne P M. A long-term study of the anti-inflammatory effect of low-dose budesonide plus formoterol versus high-dose budesonide in asthma.Am J Respir Crit Care Med 2000; 161:996–1001. [CSA]
   PubMed Web of Science ®Google Scholar
• Barnes P J. Scientific rationale for inhaled combination therapy with long-acting β2-agonists and corticosteroids.Eur Respir J 2002; 19:182–191. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Horn C R, Clark T JH, Cochrane G M. Compliance with inhaled therapy and morbidity from asthma.Respir Med 1990; 84:67–70. [CSA]
   PubMed Web of Science ®Google Scholar
• Eisner M D, Lieu T A, Capra A M, Mendoza G R, Selby J V, Blanc P D. Beta agonists, inhaled steroids, and the risk of intensive care unit admission for asthma.Eur Respir J 2001; 17:233–240. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• van der Palen J, Klein J J, van Herwaarden C LA, Zielhuis G A, Seydel E R. Multiple inhalers confuse asthma patients.Eur Respir J 1999; 14:1034–1037. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Cochrane G M. Compliance in asthma.Eur Respir Rev 1998; 8:348–350. [CSA]
   Google Scholar
• Campbell L M. Once-daily inhaled corticosteroids in mild to moderate asthma. Improving acceptance of treatment.Drugs 1999; 58(suppl 4):25–33. [CSA]
   PubMed Web of Science ®Google Scholar
• Buhl R. Budesonide/formoterol for the treatment of asthma.Expert Opin Pharmacother 2003; 4:1393–1406. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Markham A, Jarvis B. Inhaled salmeterol/fluticasone propionate combination: a review of its use in persistent asthma.Drugs 2000; 60:1207–1233. [CSA]
   PubMed Web of Science ®Google Scholar
• Miller-Larsson A, Mattsson H, Hjertberg E, Dahlbäck M, Tunek A, Brattsand R. Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue.Drug Metab Dispos 1998; 26:623–630. [CSA]
   PubMed Web of Science ®Google Scholar
• Miller-Larsson A, Jansson P, Runström A, Brattsand R. Prolonged airway activity and improved selectivity of budesonide possibly due to esterification.Am J Respir Crit Care Med 2000; 162:1455–1461. [CSA]
   PubMed Web of Science ®Google Scholar
• Thorsson L, Thunnisen F BJM, Korn S, Carlshof A, Edsbäcker S, Wouters E FM. Formation of fatty acid conjugates of budesonide in human lung tissue in vivo [abstr].Am J Respir Crit Care Med 1998; 157(suppl 3):A404. [CSA]
   Google Scholar
• Edsbäcker S, Szefler S J. Glucocorticoid pharmacokinetics: principles and clinical applications. In: Schleimer R P, Busse W W, O'Byrne P M, eds. Inhaled Glucocorticoids in Asthma: Mechanisms and Clinical Actions. New York: Marcel Dekker, 1997:381–445.
   Google Scholar
• Lipworth B J. Systemic adverse effects of inhaled corticosteroid therapy: a systematic review and meta-analysis.Arch Intern Med 1999; 159:941–955. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Arvidsson P, Beckman P, Peterson S, Lötvall J. Onset of bronchodilation of budesonide/formoterol vs. salmeterol/fluticasone in single inhalers.Pulm Pharmacol Ther 2001; 14:29–34. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Balanag V M, Yunus F, Yang P.-C, Jorup C. Budesonide/formoterol in a single inhaler is as effective and well tolerated as salbutamol in relieving acute asthma in adults and adolescents [abstr P2836].Eur Respir J 2003; 22(suppl 45):445s. [CSA]
   Google Scholar
• van der Woude H J, Boorsma M, Bergqvist P B, Winter T H, Aalbers R. Budesonide/formoterol in a single inhaler rapidly relieves methacholine-induced moderate-to-severe bronchoconstriction.Pulm Pharmacol Ther 2004; 17:89–95. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Aziz I, Wilson A M, Lipworth B J. Effects of once-daily formoterol and budesonide given alone or in combination on surrogate inflammatory markers in asthmatic adults.Chest 2000; 118:1049–1058. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bijl-Hofland I D, Cloosterman S GM, Folgering H TM, van den Elshout F J.J, van Weel C, van Schayck C P. Inhaled corticosteroids, combined with long-acting β2-agonists, improve the perception of bronchoconstriction in asthma.Am J Respir Crit Care Med 2001; 164:764–769. [CSA]
   PubMed Web of Science ®Google Scholar
• Barnes P J. Poorly perceived asthma.Thorax 1992; 47:408–409. [CSA]
   PubMed Web of Science ®Google Scholar
• Kikuchi Y, Okabe S, Tamura G, Hida W, Homma M, Shirato K, Takishima T. Chemosensitivity and perception of dyspnea in patients with a history of near-fatal asthma.N Engl J Med 1994; 330:1329–1334. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Busse W W, Chervinsky P, Condemi J, Lumry W R, Petty T L, Rennard S, Townley R G. Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma.J Allergy Clin Immunol 1998; 101:457–463. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Palmqvist M, Ibsen T, Mellén A, Lötvall J. Comparison of the relative efficacy of formoterol and salmeterol in asthmatic patients.Am J Respir Crit Care Med 1999; 160:244–249. [CSA]
   PubMed Web of Science ®Google Scholar
• Bateman E D, Britton M, Almeida J, Wixon C. Salmeterol/fluticasone combination inhaler. A new, effective and well-tolerated treatment for asthma.Clin Drug Investig 1998; 16:193–201. [CSA]
   PubMed Web of Science ®Google Scholar
• Kavuru M, Melamed J, Gross G, Laforce C, House K, Prillaman B, Baitinger L, Woodring A, Shah T. Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: a randomized, double-blind, placebo-controlled trial.J Allergy Clin Immunol 2000; 105:1108–1116. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Shapiro G, Lumry W, Wolfe J, Given J, White M V, Woodring A, Baitinger L, House K, Prillaman B, Shah T. Combined salmeterol 50 µg and fluticasone propionate 250 µg in the Diskus device for the treatment of asthma.Am J Respir Crit Care Med 2000; 161:527–534. [CSA]
   PubMed Web of Science ®Google Scholar
• Johansson G, McIvor R A, Purello D'Ambrosio F, Gratziou C, James M H. Comparison of salmeterol/fluticasone propionate combination with budesonide in patients with mild-to-moderate asthma.Clin Drug Investig 2001; 21:633–642. [CSA]
   Web of Science ®Google Scholar
• Busse W, Koenig S M, Oppenheimer J, Sahn S A, Yancey S W, Reilly D, Edwards L D, Dorinsky P M. Steroid-sparing effects of fluticasone propionate 100 µg and salmeterol 50 µg administered b.i.d. in a single product in patients previously controlled with fluticasone propionate 250 µg administered b.i.d..J Allergy Clin Immunol 2003; 111:57–65. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Jenkins C, Woolcock A J, Saarelainen P, Lundbäck B, James M H. Salmeterol/fluticasone propionate combination therapy 50/250 µg b.i.d. is more effective than budesonide 800 µg b.i.d. in treating moderate to severe asthma.Respir Med 2000; 94:715–723. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chapman K R, Ringdal N, Backer V, Palmqvist M, Saarelainen S, Briggs M. Salmeterol and fluticasone propionate (50/250 microg) administered via combination Diskus inhaler: as effective as when given via separate Diskus inhalers.Can Respir J 1999; 6:45–51. [CSA]
   PubMedGoogle Scholar
• Aubier M, Pieters W, Schlosser N, Steinmetz K-O. Salmeterol/fluticasone propionate (50/500 µg) in combination in a Diskus inhaler (Seretide) is effective and safe in the treatment of steroid-dependent asthma.Respir Med 1999; 93:876–884. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Van den Berg N J, Ossip M S, Hederos C A, Anttila H, Ribeiro B L, Davies P I. Salmeterol/fluticasone propionate (50/100 µg) in combination in a Diskus™ inhaler (Seretide™) is effective and safe in children with asthma.Pediatr Pulmonol 2000; 30:97–105. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Nelson H S, Chapman K R, Pyke S D, Johnson M, Pritchard J N. Enhanced synergy between fluticasone propionate and salmeterol inhaled from a single inhaler versus separate inhalers.J Allergy Clin Immunol 2003; 112:29–36. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bateman E D, Boushey H A, Bousquet J, Busse W W, Clark T J, Pauwels R A, Pedersen S E, GOAL Investigators Group. Can guideline-defined asthma control be achieved? The Gaining Optimal Asthma ControL Study.Am J Respir Crit Care Med 2004; 170:836–844. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Zetterström O, Buhl R, Mellem H, Perpiña M, Hedman J, O'Neill S, Ekstrom T. Improved asthma control with budesonide/formoterol in a single inhaler, compared with budesonide alone.Eur Respir J 2001; 18:262–268., [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rosenhall L, Heinig J H, Lindqvist A, Leegaard J, Stahl E, Bergqvist P B. Budesonide/formoterol (Symbicort®) is well tolerated and effective in patients with moderate persistent asthma.Int J Clin Pract 2002; 56:427–433. [CSA]
   PubMed Web of Science ®Google Scholar
• Rosenhall L, Elvstrand A, Tilling B, Vinge I, Jemsby P, Stahl E, Jerre F, Bergqvist P B. One-year safety and efficacy of budesonide/formoterol in a single inhaler (Symbicort Turbuhaler) for the treatment of asthma.Respir Med 2003; 97:702–708. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Lalloo U J, Malolepszy J, Kozma D, Krofta K, Ankerst J, Johansen B, Thomson N C. Budesonide and formoterol in a single inhaler improves asthma control compared with increasing the dose of corticosteroid in adults with mild-to-moderate asthma.Chest 2003; 123:1480–1487. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Bateman E D, Bantje T A, Joao Gomes M, Toumbis M, Huber R, Naya I, Eliraz A. Combination therapy with single inhaler budesonide/formoterol compared with high dose of fluticasone propionate alone in patients with moderate persistent asthma.Am J Respir Med 2003; 2:275–281. [CSA]
   PubMedGoogle Scholar
• Palmqvist M, Persson G, Lazer L, Rosenborg J, Larsson P, Lötvall J. Inhaled dry powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency.Eur Respir J 1997; 10:2484–2489. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Buhl R, Creemers J P.H.M, Vondra V, Martelli N A, Naya I P, Ekstrom T. Once-daily budesonide/formoterol in a single inhaler in moderate persistent asthma.Respir Med 2003; 97:323–330. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Chisholm S L, Dekker F W, Knuistingh Neven A, Petri H. Once-daily budesonide in mild asthma.Respir Med 1998; 92:421–425. [CSA]
   PubMed Web of Science ®Google Scholar
• Herjavecz I, Blomqvist P, Serrano A. Efficacy of once- and twice-daily administration of budesonide via Turbuhaler® as initial therapy in patients with mild persistent asthma.Respir Med 1999; 93:230–235. [CSA]
   PubMed Web of Science ®Google Scholar
• McFadden E R, Casale T B, Edwards T B, Kemp J P, Metzger W J, Nelson H S, Storms W W, Neidl M J. Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma.J Allergy Clin Immunol 1999; 104:46–52. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Foresi A, Morelli M C, Catena E, on behalf of the Italian Study Group. Low-dose budesonide with the addition of an increased dose during exacerbations is effective in long-term asthma control.Chest 2000; 117:440–446. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Ställberg B, Olsson P, Jörgensen L A, Lindarck N, Ekström T. Budesonide/formoterol adjustable maintenance dosing reduces asthma exacerbations versus fixed dosing.Int J Clin Pract 2003; 57:656–661. [CSA]
   PubMed Web of Science ®Google Scholar
• Leuppi J D, Salzberg M, Meyer L, Bucher S E, Nief M, Brutsche M H, Tamm M. An individualized, adjustable maintenance regimen of budesonide/formoterol provides effective asthma symptom control at a lower overall dose than fixed dosing.Swiss Med Wkly 2003; 133:302–309. [CSA]
   PubMed Web of Science ®Google Scholar
• FitzGerald J M, Sears M R, Boulet L.-P, Becker A B, McIvor A R, Ernst P, Smiljanic-Georgijev N M, Lee J S, Canadian Investigators. Adjustable maintenance dosing with budesonide/formoterol reduces asthma exacerbations compared with traditional fixed dosing: a five-month multicentre Canadian study.Can Respir J 2003; 10:427–434. [CSA]
   PubMedGoogle Scholar
• Aalbers R, Backer V, Kava T T, Omenaas E R, Sandström T, Jorup C, Welte T. Adjustable dosing with budesonide/formoterol compared with fixed dosing salmeterol/fluticasone in moderate to severe asthma.Curr Med Res Opin 2004; 20:225–240. [CSA]
   PubMed Web of Science ®Google Scholar
• O'Byrne P M, Bisgaard H, Godard P P, Pistolesi M, Palmqvist M, Zhu Y, Ekstrom T, Bateman E D. Budesonide/formoterol combination therapy as both maintenance and reliever medication in asthma.Am J Respir Crit Care Med 2005; 171:129–136. [CSA]
   PubMed Web of Science ®Google Scholar
• Scicchitano R, Aalbers R, Ukena D, Manjra A I, Fouquert L, Centanni S, Boulet L P, Naya I P, Hultquist C. Efficacy and safety of budesonide/formoterol single inhaler therapy versus a higher dose of budesonide in moderate to severe asthma.Curr Med Res Opin 2004; 20:1403–1418. [CSA], [CROSSREF]
   PubMed Web of Science ®Google Scholar
• Rabe K F, Pizzichini E, Ställberg B, Romero S, Balanzat A, Soerensen T, Atienza T. Single inhaler therapy with budesonide/formoterol provides superior asthma control compared with fixed dosing with budesonide plus terbutaline as needed [abstr 360].J Allergy Clin Immunol 2004; 113(suppl 2):S116. [CSA], [CROSSREF]
   Google Scholar